Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus MR4 in De Novo Bone Marrow Transplant Recipients
NCT00189761Phase 2Completed
- Sponsor
- Astellas Pharma
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus in graft-versus-host disease (GVHD), sponsored by Astellas Pharma. Primary endpoint: Incidence of acute Graft-Versus-Host Disease at 100 days. Status: completed.
02
Drugs
tacrolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00189761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189761.